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ICOSL/ICOS are costimulatory molecules pertaining to immune checkpoints; their binding
transduces signals having anti-tumor activity. Osteopontin (OPN) is here identified as a
ligand for ICOSL. OPN binds a different domain from that used by ICOS, and the binding
induces a conformational change in OPN, exposing domains that are relevant for its functions.
Here we show that in vitro, ICOSL triggering by OPN induces cell migration, while inhibiting
anchorage-independent cell growth. The mouse 4T1 breast cancer model confirms these
data. In vivo, OPN-triggering of ICOSL increases angiogenesis and tumor metastatization. The
findings shed new light on ICOSL function and indicate that another partner beside ICOS may
be involved; they also provide a rationale for developing alternative therapeutic approaches
targeting this molecular trio.
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ICOSL (B7-H2, CD275) belongs to the B7 family and regulatesthe immune response by delivering costimulatory signalsthrough ICOS, a surface receptor mainly expressed by acti-
vated T cells1–4. ICOSL is constitutively expressed by antigen-
presenting cells (APCs) as well as some non-lymphoid cells,
including several tumor-cell types5,6. The expression of ICOSL in
non-lymphoid tissues, such as the brain, lungs, heart, kidney,
liver, and gut, suggests that it regulates the activation of antigen-
experienced effector/memory T cells. However, ICOSL is
expressed at high levels in T helper follicular (TFH) cells, and
ICOS deficiency has been associated with defective formation of
lymphoid follicles in mice and in the development of common
variable immunodeficiency in humans7.
The main known function of ICOSL is triggering ICOS, which
serves as a costimulatory molecule for T cells and, supports
cytokine-driven polarization of T helper (Th) cells. Conversely,
ICOS binding to ICOSL also triggers “reverse signaling” into the
ICOSL expressing cell. In particular, triggering of ICOSL by a
recombinant soluble form of ICOS (ICOS-Fc) inhibits adhesive-
ness and migration of human umbilical vein endothelial cells
(HUVECs) and several tumor-cell lines, and treatment of mice
with ICOS-Fc inhibits the development of experimental lung
metastases in the B16 melanoma model4,8. Other effects of ICOSL
triggering have been detected in dendritic cells (DC), whose
treatment with ICOS-Fc not only inhibits cell migration and
adhesion, but also modulates cytokine secretion and antigen
cross-presentation in class I MHC molecules9–11.
Osteopontin (OPN) is a phosphoprotein, secreted by several
cell types, such as macrophages, DC and Th cells; it can func-
tion both as a matricellular protein and a cytokine mediating
several biological functions. These include migration, adhesion,
activation of inflammatory cells, and modulation of T cell
activation supporting differentiation of proinflammatory type 1
(Th1) and type 17 (Th17) Th cells12. It is highly expressed in
several types of tumors, being secreted by both tumor and
microenvironment cells, and is implicated in promoting tumor
invasion and metastatic dissemination13. Importantly, current
research, indicates that OPN inhibition would be a good ther-
apeutic approach to metastatic disease. In preclinical models,
OPN knockdown using RNAi, aptamers, or antibodies, have
shown to have active roles in cancer treatment. Nevertheless,
only a small number of these findings translate into clinical
practice14.
OPN’s pleiotropic activities are partly due to its capacity to
interact with multiple ligands, including several cell-surface recep-
tors, namely several integrins and CD44, calcium, and heparin.
OPN’s biological functions are also influenced by post-translational
modifications, such as phosphorylation, glycosylation, and protein
cleavage mediated by thrombin and metalloproteinases15.
OPN is an intrinsically disordered protein (IDP), which chal-
lenges the traditional structure-function paradigm of biologically
relevant proteins16. Indeed, OPN lacks a well-folded crystallizable
structure, but behaves either as an extended and flexible poly-
peptide or as a globular protein. This confers to OPN the ability
to adopt different functional structures by folding upon binding
and to interact with multiple binding partners17. Thrombin
cleaves OPN in the middle of the molecule, near to an RGD
motif, and generates two fragments with slightly different func-
tional activities12.
Recent findings depict a functional network between ICOS,
ICOSL, and OPN. Firstly, all these molecules support Th17 cell
responses. Secondly, they are involved in cell migration, which is
induced by OPN and inhibited by ICOS-mediated ICOSL trig-
gering10. Thirdly, they are involved in the bone metabolism, since
OPN is a key bone component produced by osteoblasts, whereas
ICOS-mediated triggering of ICOSL expressed by osteoclasts
(OC) inhibits OC differentiation from monocytes and bone
resorption activity of mature OC in vitro, and the development of
osteoporosis in vivo18.
A prior study showed that HUVECs treatment with ICOS-Fc
inhibits ERK phosphorylation induced by OPN, but not that
induced by ATP8. More recent work found that ICOS-Fc inhibits
HUVEC tubulogenesis induced by OPN, but not that induced by
VEGFα19. Collectively, these data suggest an intersection between
ICOS/ICOSL and OPN functions, and lead to this study aimed at
investigating the crosstalk among this molecular trio.
Here, we show that OPN binds ICOSL at a different domain
than the one used by ICOS. Activation of ICOSL by OPN induces
cell migration in vitro, angiogenesis, and tumor metastatization
in vivo.
Results
Expression of ICOSL is required for OPN-mediated cell
migration and is blocked by ICOS-Fc. The effect of ICOSL
triggering by ICOS-Fc was evaluated in OPN-induced migration
of several human tumor-cell lines expressing high (ICOSLhigh) or
low (ICOSLlow) levels of ICOSL (Supplementary Figs. 1a, b,
respectively). In parallel, the effect on migration induced by 20%
FBS was assessed. Results showed that both OPN and FBS
induced substantial migration of the ICOSLhigh cell lines (M14
and JR8), which was inhibited by ICOS-Fc (Fig. 1a). By contrast,
ICOSLlow (PCF2 and A2058) cell migration was induced by FBS
but not by OPN (Fig. 1b). Treatment with ICOS-Fc did not affect
the migration of the ICOSLlow cell lines in any setting.
Since these data suggest that ICOSL expression is required for
OPN-induced migration, the study assessed whether overexpres-
sion of ICOSL in the A2058 cells conferred migration capability
in response to OPN. A2058 cells transfected with a plasmid
encoding for ICOSL (Supplementary Fig. 1c) acquired migratory
capability in response to OPN, and this migration was inhibited
by ICOS-Fc (Fig. 1c).
To assess the role of ICOSL in OPN-induced migration in a
different and non-tumor-derived cell model, HUVECs, which are
known to express ICOSL, were tested. To silence ICOSL,
HUVECs were transfected with two different siRNA targeting
ICOSL (siRNA1 and siRNA2) or scrambled siRNA (siRNAscr) as
control. Real-time PCR confirmed statistically significant silen-
cing of ICOSL in cells transfected with siRNA1 and siRNA2,
compared with siRNAscr (Fig. 1d). Differentially from siRNAscr,
HUVECs silenced for ICOSL did not respond to OPN while
maintain their response to VEGF (Fig. 1e).
Taken together, these findings show that OPN-induced
migration requires the presence of ICOSL.
To investigate which portion of ICOSL is required for
responsiveness to OPN-induced migration, OPN pro-migratory
activity was assessed in not expressing ICOSL-HeLa cells (cervical
cancer cell line), in comparison with HeLa transfected for full-
length ICOSL (ICOSLWT), or an intracellular tailless mutant
(ICOSLTL), or a mutant composed of the transmembrane and
intracellular portions plus a poly-histidine sequence substituting
the extracellular portion (ICOSLIC) (Fig. 1f). Expression of ICOSL
was assessed by flow cytometry using an anti-ICOSL mAb for
ICOSL and ICOSLTL, and an anti-poly-His PE-conjugated mAb
for ICOSLIC (Fig. 1g). We found that only HeLa transfected for
full-length ICOSL (ICOSLWT) molecule gained the ability to
migrate toward OPN, whereas those transfected with either
ICOSLIC or ICOSLTL did not. By contrast, all these cell lines
displayed a similar migration in response to FBS (Fig. 1h).
OPN binds the extracellular portion of ICOSL. These data
suggest that OPN triggers pro-migratory signals through ICOSL
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and open the possibility of a direct binding between the two
molecules. To test this hypothesis, an ELISA-based interaction
assay was run, using recombinant OPN as the capture protein,
and evaluating the binding of titrated amounts of soluble
recombinant ICOSL-Fc. A commercial OPN produced in mam-
malian cells was used to ensure the presence of the physiological
post-translational modifications. Results showed that ICOSL
displays concentration-dependent binding to OPN (Fig. 2a). The
same experiments were also performed using a 1:1 mixture of
ICOSL-Fc and ICOS-Fc to assess any competition between OPN
and ICOS-Fc for ICOSL binding or using ICOS-Fc alone to rule
out the interaction with the Fc domain. Results showed that the
presence of ICOS-Fc did not inhibit ICOSL-Fc binding to OPN,
and ICOS-Fc alone did not bind to OPN (Fig. 2a). Since the
commercial OPN corresponds to OPN-b, a splicing variant
missing the exon 5, the full-length OPN (OPN-a) was produced
in an eukaryotic system and its binding capability to ICOSL-Fc
tested by ELISA. Further, the role of OPN post-translational
modifications in OPN/ICOSL binding was assessed, using a
recombinant OPN (OPN-GST) produced in E. Coli. As shown,
with both preparations, the results were similar to those obtained
using the commercial OPN-b (Supplementary Fig. 2), indicating
that OPN/ICOSL binding does not require post-translational
modifications. To strengthen these results, reciprocal ELISA was
Fig. 1 Expression of ICOSL is required for OPN-mediated cell migration and is blocked by ICOS-Fc. a M14 and JR8 cell lines with high expression of
ICOSL (ICOSLhigh), b PCF2 and A2058 cell lines with low ICOSL expression (ICOSLlow), and c A2058 ICOSLhigh-transfected cells were treated or not with
ICOS-Fc (2 μg ml−1) and then plated onto the apical side of Matrigel-coated filters in 50 μl serum-free medium. The cells were allowed to migrate for 8 h to
the lower chamber containing 10 μg ml−1 OPN or 20% FBS as chemotactic stimuli. The cells that migrated to the bottom of the filters were stained using
crystal violet and all counted (quadruplicate filter) using an inverted microscope. Dotted line refers to untreated cells (NT). Data are expressed as the
number of migrated cells per high-power field (***P < 0.001 refers baseline, ##P < 0.001 refers to OPN-induced migration (n= 5 technical replicate).
d Relative quantification of ICOSL gene in silenced HUVEC using siRNA1 and siRNA2; cells treated with non-specific siRNA (SCR-siRNAscr) served as
controls. Data are shown as gene expression relative to the expression of the endogenous control GAPDH (2−ΔCtmethod) and T test was used; **P < 0.01
(n= 3–4 technical replicate). e Assessment of migration of silenced HUVECs, via a Boyden chamber assay, in response to OPN and VEGF (***P < 0.001
refers to OPN-mediated migration in scr sample) (n= 7–8 technical replicate). f Schematic overview of the three different mutants of ICOSL generated.
g ICOSL expression on transfected HeLa cells as assessed by flow cytometry. In the dot plots, gray, gray dotted, and black lines indicate the intracytoplasmic
mutant (IC), the tailless mutant (TL), and the wild-type molecule (WT), respectively. The black filled histogram shows the negative control. h HeLa migration
induced by OPN or FBS was assessed via a Boyden chamber assay. Cells migration was evaluated as described in a, b, and c (**P < 0.01 refers to baseline)
(n= 5 technical replicate). All data are expressed as means ± standard error. For migration experiments one-way ANOVA with post-hoc Tukey multi-
comparison test was used.
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performed by coating the plate with ICOSL-Fc and testing
binding of titrated amounts of commercial OPN-b. In this case,
too, OPN-b displays concentration-dependent binding to ICOSL
(Supplementary Fig. 3).
To further confirm the OPN/ICOSL interaction, pull-down
experiments were run with recombinant OPN-b and ICOSL-Fc.
Precipitated proteins were detected with an anti-OPN antibody.
Results showed that OPN co-immunoprecipitated with ICOSL-
Fc, confirming the ELISA results (Fig. 2b).
Collectively, these data suggest that: (i) the extracellular portion
of ICOSL binds directly to OPN, (ii) this interaction occurs at a
different binding site compared to ICOS-Fc, (iii) OPN binding to
ICOSL is independent of its post-translational modifications.
To evaluate the OPN/ICOSL interaction in a tissue setting, a
proximity ligation assay (PLA) was run that enables binding
between proteins that reside at <40 nm distance in tissue sections
to be detected. PLA assay on kidney sections (expressing both
OPN and ICOSL) showed sparse distinct spots of interaction in
wild-type C57BL/6 mice and multiple diffuse spots of interaction
in MRL-lpr mice, (Fig. 2c). MRL-lpr mice, spontaneously develop
glomerulonephritis, increasing expression level of both proteins and
have been chosen as a model hyper-expressing both molecules20,21.
By contrast, no PLA signal was detected in OPN−/− and ICOSL−/−
mice, chosen as negative controls.
Conformational analysis of the OPN/ICOSL complex by lim-
ited proteolysis. Limited proteolysis and chemical cross-linking
experiments were employed for conformational studies, to map
the interaction regions of OPN and ICOSL. We optimized con-
ditions, to aim enzymatic activity only towards the most exposed
and flexible regions, so that regions of OPN and ICOSL, exposed
to proteolysis in the isolated proteins and hidden in the complex,
may be identified. These may be part of the protein-protein
interaction region. Since OPN was more susceptible to hydrolysis
than ICOSL-Fc with an enzyme vs. substrate ratio (E:S) 50 times
lower for OPN than for ICOSL-Fc, using either trypsin or chy-
motrypsin. These data suggest OPN has either greater flexibility
or a less compact structure than ICOSL-Fc, in line with the
intrinsically disordered nature of OPN16. The experiments were
thus performed on the complex using the lower E:S ratio, thus
giving priority to the conformational analysis of OPN rather than
ICOSL-Fc, whose digestion would require more protease. As
shown in Fig. 3, some differences among the isolated proteins and
the digestion profiles of the complex were highlighted. As
expected, in both tryptic and chymotryptic hydrolyses, a large
amount of ICOSL-Fc remained undigested, without substantial
changes, also in the material digested from the complex. By
contrast, the proteolytic profiles of isolated OPN displayed low-
molecular-weight bands (Figs. 3a-1 to 5) that are absent upon
Fig. 2 OPN binds the extracellular portion of ICOSL. a ELISA-based interaction assay. Recombinant OPN was used as capture protein on 96 well plates
and the binding of titrated amounts of soluble recombinant ICOSL-Fc was evaluated alone (black circle) or mixed 1:1; with ICOS-Fc (black square) or of
ICOS-Fc alone (black triangle). Data are expressed as means ± standard error (n= 3 technical replicate). b Pull-down assay. Schematic presentation of the
pull-down assay used to detect ICOSL/OPN binding, in which ICOSL-Fc was used as a Sepharose-bound bait protein incubated (first lane) with OPN. The
second (ICOSL-Fc) and third lanes (OPN) represent the negative controls in which only one of the two interactors were present. The membrane was
blotted with an anti-OPN polyclonal antibody. A representative immunoblot of two independent experiment is shown (uncropped blot is shown in
Supplementary Fig. 6). c Proximity Ligation Assay (PLA) in mice kidneys. PLA signal (violet) shows protein-protein interactions between ICOSL and OPN;
C57BL/6J and MRL/Lpr chosen as positive controls, while OPN-/- and ICOSL-/- as negative ones. Four images at a magnification of ×40 were analyzed for
each sample, considering 3 mice per group (n= 3 biological replicate).
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digestion of the OPN/ICOSL-Fc complex, suggesting that the
cleavage sites that generate them are located in regions that are
exposed in isolated OPN but buried upon interaction with ICOSL
(Fig. 3a). These low-molecular-weight bands of OPN proteolysis
were analyzed using a mass mapping approach. Results showed
that the bands with electrophoretic mobility of about 25–26 kDa
(bands 1, 2, and 4) mapped in the middle of OPN, upstream of
position 130, suggesting that residues close to this amino acid
residue are exposed and accessible to proteases in the isolated
protein, but become hidden in the OPN/ICOSL-Fc complex.
Bands 3 and 5 mapped in the same OPN C-terminal portion as
bands 1, 2, and 4, but they covered a substantially shorter
sequence, which suggests that they were generated by sub-
digestion events (Fig. 3b). These data suggest that the region of
OPN interaction with ICOSL-Fc is located in the central part of
the protein near to the RGD motif and the physiological
thrombin cleavage site. These experiments gave no hint con-
cerning the ICOSL-Fc, since it was substantially undigested at the
E:S ratio used. This is a common and unavoidable effect of
operating with two proteins having such different susceptibilities
to proteases.
Conformational analysis of the OPN/ICOSL complex by cross-
linking. Additional experiments were carried out using the
bifunctional cross-linker 3,3′dithiobis(sulfosuccinimidyl propio-
nate) (DTSSP). DTSSP is a lysine–lysine specific reactive with a
spacer arm 12Ǻ in length that can be cleaved under reducing
conditions. Cross-linkers can also provide information on the
tertiary structure since they may be considered as actual chemical
labels: the presence/absence of DTSSP-mediated modification of
specific lysines provides an indication of their exposure within
isolated proteins or the complex. An excess of DTSSP was added
to the pre-formed complex between GST-OPN and ICOSL. As
control, the same treatment was applied to isolated GST-OPN
and ICOSL. Then, the samples were separated by non-reducing
naïve-PAGE and stained by colloidal Coomassie (Fig. 4a). Lane 2,
where the complex was loaded after reaction with DTSSP, shows
the appearance of a 100 kDa band (marked with a bracket) with
an electrophoretic mobility higher than those corresponding to
each isolated protein (marked with arrows), as expected for the
GST-OPN/ICOSL complex. This band was cut out and in situ
digested with trypsin, in non-reducing conditions to preserve the
integrity of the cross-linker moiety. LC-MS/MS and MALDI-MS
analyses of the peptide mixture detected the presence of peptides
derived from both OPN and ICOSL, which shows that the band
was generated by DTSSP-mediated covalent linking of GST-OPN
and ICOSL and confirms direct interaction between the two
molecules. However, the mass spectrometer data analysis did not
provide direct and conclusive identification of the OPN–ICOSL
cross-linking sites. Detecting actual cross-linked peptides within
digested mixtures has long been problematic, because some cross-
linked peptides are too large to detect, their fragmentation is
more complicated than usual linear peptides, and not every
protein or peptide is cross-linked in the same way22,23.
To gain insight into the OPN/ICOSL surface topology24, an
aliquot of the peptide sample produced by digestion of the band
containing the cross-linked proteins was reduced and analyzed by
MALDI-MS and LC-MS/MS. Overall comparison of MS data
from oxidized and reduced samples was informative concerning
lysine exposure in OPN and ICOSL, whether analyzed as isolated
molecules or their complex (Tables 1, 2).
With regard to ICOSL, all expected peptides containing a lysine
residue were identified, in both isolated ICOSL and the complex,
except for K174. This residue was recognized by trypsin in isolated
and untreated ICOSL, generating the peptide 175–194; once
modified, the residue escaped trypsin hydrolysis, and occurred
within an excessively large tryptic peptide that would be difficult
to detect. In conclusion, failure to detect the peptide containing
K174 in the complex following DTSSP treatment suggests that the
protein regions including this residue might be involved in OPN
Fig. 3 Conformational analysis of the OPN/ICOSL complex by limited proteolysis. a SDS-PAGE of proteolytic mixture of OPN, ICOSL-Fc, and their
complex, after 30min of proteolysis with trypsin (left panel) and chymotrypsin (right panel). Lane M: molecular weight markers; lane 1: OPN (5 µg)
digested with trypsin, E:S 1:5000; lane 2: OPN/ICOSL complex digested with trypsin, E:S 1:5000; lane 3: ICOSL (5 µg) digested with trypsin, E:S 1:100; lane
4: OPN (2 µg); lane 5: ICOSL (2 µg); lane 6: OPN (5 µg) digested with chymotrypsin, E:S 1:5000; lane 7: OPN–ICOSL 2:1 complex digested with
chymotrypsin, E:S 1:5000; lane 8: ICOSL (5 µg) digested with chymotrypsin, E:S 1:100. b Sequence coverages obtained by tryptic mass mapping
experiments performed on bands 1, 2, 3, 4, and 5 which were discriminant among isolated proteins and complex. In bold the regions mapped by LC-MS/MS
analyses. RGD is boxed in red and Thrombin cleavage site in pink.
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binding or in conformational changes (Fig. 4b). With regard to
OPN, in both the complex and the isolated GST-OPN, the lysines
K222, K241, K249, and K268 were labeled with a single dead-end
molecule of DTSSP in all cases. Since these residues are equally
exposed in both isolated and complexed GST-OPN, the
possibility that they are located in regions involved in the
interaction with ICOSL may be ruled out. Moreover, peptides
221–244 and 249–271 displayed a mass increased of 174 Da
(accounting for the introduction of a DTSSP moiety cross-linking
two lysines within the linear peptides), suggesting the occurrence
of intramolecular cross-links between K222 and K241 and between
K249 and K268. Therefore, the two pairs of cross-linked lysines are
spatially close, and their side chains are oriented appropriately to
be cross-linked.
K247 was always detected in peptides including K249, both in the
isolated protein (242–268 and 245–268+ 1CLH2O) and in the
complex (245–268+ 1CLH2O); although a certain assignment of
its state is not allowed, it is plausible to suppose it behaves
similarly to K241 and K249 given its nearby location (Fig. 4b).
Residues K20, K30, K35, K51, K70 K77, and K203 were in no case
labeled by DTSSP within the complex, nor were they generated by
a cleavage event in correspondence with a non-modified lysine.
These findings suggest that, in the GST-OPN/ICOSL complex as
well as in OPN alone, none of these residues are ever exposed to
be modified by the cross-linking agent.
Intriguingly, K170, K172, and K173 were modified by DTSSP only
when OPN was bound to ICOSL, suggesting that the region
including these three residues undergoes a significant conforma-
tional change upon complex formation, exposing residues whose
side chains are concealed or are involved in local interactions in
the isolated protein. Noteworthy, these three lysine residues are
located next to the thrombin cleavage site (R168–S169) and are
thus downstream of both the RGD motif and the potential
interaction region with ICOSL, as suggested by the limited
proteolysis experiments. When the cross-linked complex was
reduced and alkylated, the peptide 272–299 was identified,
suggesting that K299 may not be modified by DTSSP. Moreover,
this peptide, which contains three other lysine residues (K290,
K292, and K296), was found to be doubly modified: upon both
reduction and alkylation reactions. This finding suggests that two
of these three lysine residues are labeled within the complex. The
reduced and alkylated forms of this peptide might be generated
Fig. 4 Conformational analysis of the OPN/ICOSL complex by cross-linking experiments. a Non-reducing SDS-PAGE of DTSSP treated samples. Lane 1:
GST-OPN; lane 2: complex GST-OPN–ICOSL; lane 3: ICOSL. The bracket indicates the presence of a faint band, migrating as per the electrophoretic
mobility expected for the complex GST-OPN–ICOSL. ICOSL b and OPN c sequences with all lysine residues indicated in red, and lysines modified with
squares and triangles, in both the isolated proteins (upper panels) and the complex (lower panels). Filled squares indicate lysines modified as dead-end by
DTSSP; empty squares indicate those modified as dead-ends or intra-molecule cross-linking. Black triangles on OPN/ICOSL complex indicate lysines found
modified in the complex, before and after the REDCAM reaction. Gray triangles represent lysines found modified only in the complex after the REDCAM
reaction. Empty triangles are lysines found modified only before the REDCAM reaction. RGD is boxed in green and thrombin cleavage site in orange.
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Table 1 List of peptides identified by the mass mapping procedure and relative to: isolated OPN, isolated OPN+DTSSP
(indicated with CL); OPN/ICOSL complex +DTSSP (indicated with CL); OPN/ICOSL+DTSSP (indicated with CL) following
reduction and alkylation treatment (indicated with CAM).
Lysine Residue Peptides from OPN Peptides from (OPN+
DTSSP)
Peptides from the complex
(OPN/ICOSL+DTSSP)
Peptides from the complex (OPN/ICOSL+
DTSSP) REDCAM
K20 – – – –
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Exp 3703.41
Theor 3703.61
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either from inter- or from intramolecular cross-links, not ruling
out the possible involvement of this C- terminal region in ICOSL
binding (Fig. 4c).
ICOSL binds both the N-term and the C-term thrombin-generated
fragments of OPN. Collectively these data suggest that, on ICOSL, the
OPN binding site is located in the IgC domain (Fig. 5a), whereas
within OPN, two different binding sites for ICOSL exist. One is
upstream of the RGD domain, and the other on the C-terminal
portion of the protein (Fig. 5b). Since the thrombin cleavage site in
OPN is in the middle of these putative sequences, the ability to bind
ICOSL displayed by recombinant forms of the N-term (aa 17–167)
and C-term (aa 168–314) portions of OPN was tested; these corre-
spond to the two fragments generated by the physiologic thrombin
cleavage of the whole OPN (Fig. 6a)12. ELISA assay showed that both
the OPN portions bind to ICOSL, but to a lesser extent than the full-
length protein (Fig. 6b). This supports the existence of multiple ICOSL
binding sites in OPN.
ICOSL expression promotes tumor-cell migration while inhi-
biting anchorage-independent cell growth. To better investigate
the effects of the OPN/ICOSL interaction on tumor progression
and metastatization, we employed the orthotopic 4T1 mam-
mary carcinoma which spontaneously metastasizes to the
lungs. Since 4T1 cells secrete high levels of OPN, but do not
express ICOSL, the cells were stably transfected with a plasmid
encoding ICOSL, to generate 4T1 cells expressing high levels of
ICOSL (4T1ICOSL). Intriguingly, 4T1ICOSL cells expressed more
OPN than the parent cells, suggesting that ICOSL may upre-
gulate OPN in these cells (Supplementary Fig. 4a). In line with
previous findings, migration assays showed that OPN induces
migration of 4T1ICOSL cells but not of 4T1 and it was inhibited
by ICOS-Fc (Fig. 7a).
To compare the neoplastic potential of 4T1 and 4T1ICOSL cells,
their growth kinetic in adhesion-dependent and -independent
conditions was evaluated, in the presence and absence of OPN.
Adhesion-dependent growth, assessed by growing cells in
standard culture plates, showed that 4T1 and 4T1ICOSL cells
display the same growth kinetic, even in the presence of OPN
(Supplementary Fig. 4b). Conversely, adhesion-independent
growth, assessed by culturing cells in soft agar, showed that
4T1ICOSL cells grow less strongly than 4T1 cells. Interestingly,
addition of OPN further inhibited the growth of 4T1ICOSL cells in
a dose-dependent manner but left that of 4T1 cells unchanged
(Fig. 7b).
These results suggest that expression of ICOSL decreases the
growth potential of 4T1 cells but increases their migratory
activity, and that these effects depend on OPN.
Tumor growth, angiogenesis and dissemination are influenced
by OPN/ICOSL binding. To assess the effect of the OPN/ICOSL
interaction in tumor, parent 4T1 or 4T1ICOSL were injected into
syngeneic mice (Fig. 8a). We observed that, even though the
tumor volume was significantly smaller in 4T1ICOSL tumors as
compared with 4T1 (grown and measured in parallel- Fig. 8b) the
number of lung metastasis was similar in both the tumor types
(Fig. 8c). No effect was observed on mice body weight (Supple-
mentary Fig. 5). These results are in line with the initial
hypothesis of the pro-invasive role of the OPN/ICOSL interaction
in the tumor context.
We checked OPN and ICOSL expression within the tumor by
immunofluorescence and we found that 4T1ICOSL tumors
expressed high levels of both OPN and ICOSL and displayed a
high degree of colocalization. By contrast, in 4T1 tumors ICOSL
expression was very low, possibly ascribable to stromal cells and
infiltrating immune cells (Fig. 8d). PLA analysis revealed high
signals in 4T1ICOSL tumors; notably these signals were more
abundant, aggregated and organized along a linear front in the
tumor periphery. Conversely, few signals were detected in 4T1
tumors (Fig. 8e).
The impact of the OPN/ICOSL interaction on the tumor
microenvironment was then investigated, focusing on angiogen-
esis, which favors tumor dissemination. Confocal analysis showed
that 4T1ICOSL tumors displayed higher vessel density than 4T1
tumors (Fig. 8f).
Discussion
This study shows that ICOSL is a hitherto-undescribed receptor for
OPN and that interaction between the two is involved in pro-
moting endothelial and tumor-cell migrations. Moreover, although
the OPN/ICOSL interaction may restrain primary tumor growth
both in vitro and in vivo, it seems to favor its potential metastatic
dissemination, increasing tumor angiogenesis.
The direct interaction between OPN and ICOSL is shown by
their bidirectional ability to bind to one another, as detected by
ELISA-based assays and confirmed by pull-down experiments.
These experiments also show that ICOS and OPN bind different
sites of ICOSL, since they do not compete for binding. This model
was confirmed by the chemical cross-linking experiments, sug-
gesting that the OPN binding site on ICOSL involves a region
around K174 which is located in the membrane proximal IgC
domain of ICOSL, whereas ICOS is known to bind the membrane
distal to the IgV domain.
With regard to OPN, the limited proteolysis approach maps
the ICOSL binding site in the central part of OPN, upstream of
the RGD motif, and the thrombin cleavage site. Furthermore,
cross-linking experiments indicate that the region downstream
the RGD domain (including K170, K172, and K173) becomes
exposed upon ICOSL binding, which in turn indicates that,
although OPN is known to behave as an IDP in solution16, it may
acquire a specific conformation in the complex with ICOSL. This
conformational change might influence accessibility of the nearby
Table 1 (continued)
Lysine Residue Peptides from OPN Peptides from (OPN+
DTSSP)
Peptides from the complex
(OPN/ICOSL+DTSSP)
Peptides from the complex (OPN/ICOSL+
DTSSP) REDCAM
K296 – – – 272–299 (+2CL+ 2CAM)
Exp 3703.41
Theor 3703.61
K299 – – – 272–299 (+2CL+ 2CAM)
Exp 3703.41
Theor 3703.61
Lysine residue positions within the OPN sequence are shown together with the identified peptides, their molecular weights expressed as monoisotopic, and the experimental molecular weight obtained
by MALDIMS or nanoLC-MS/MS analyses.
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thrombin (R168S169) and (S162LAYGLR168) MMP3/7 cleavage
sites. This may be biologically relevant, since the full-length OPN,
and each fragment generated by its enzymatic processing in
inflammatory conditions, have partly distinct activities12. For
instance, full-length OPN induces both cell adhesion and
migration, whereas the N-terminal and C-terminal fragments
have selective effects on cell adhesion and cell migration,
respectively. Moreover, transglutaminase-cross-linked OPN,
which forms proteolysis-resistant inactive OPN polymers, reduces
breast cancer cell invasion and migration in vitro25. Conversely,
the OPN fragments generated by thrombin cleavage increase
hepatocellular carcinoma cell invasion26.
Since the putative interaction region, shown by the limited
proteolysis experiments to be the OPN region located upstream of
the thrombin cleavage site (R168S169), does not contain lysine
residues, for the long stretch to K77 the cross-linking experiments
were uninformative for that region. However, they were infor-
mative concerning the possible existence of a second interaction
site for ICOSL, comprising the OPN residues K290, K292, and K296,
located close to the OPN C-terminus. Experiments using
recombinant forms of OPN, corresponding to the C- and N-
terminal fragments generated by thrombin, confirmed that both
fragments can bind ICOSL, although to lesser extents than the
full-length molecule. The finding that bacteria-produced OPN
can bind to ICOSL indicates that eukaryotic post-translational
modifications, such as phosphorylation and glycosylation27,
which are considered important in modulating some OPN
functions, are not required for binding. The interaction between
OPN and ICOSL was also confirmed, ex vivo, by PLA, showing
that ICOSL and OPN interact in tissues that co-express them in
close proximity, like in kidney sections; this is particularly evident
in the chronic glomerulonephritis context spontaneously devel-
oped by MRLlpr/lpr mice where both molecules are expressed at
high levels20,21. Their colocalization was detected by both
immunofluorescence and PLA analysis also in 4T1ICOSL tumors.
Notably, the two proteins are strongly expressed especially at the
invasive front of the tumor, corroborating their involvement in
cancer invasion. Indeed, despite the dimensions of the primary
tumors, which are significantly smaller in 4T1ICOSL then in 4T1
mice, both groups display a similar number of lung metastasis.
Based on the obtained results, our hypothesis is that OPN/ICOSL
interaction may favor the metastatic activity of 4T1ICOSL tumors
by enhancing both tumor-cell migration and angiogenesis.
Indeed, OPN is a known proangiogenic factor, and this study
Table 2 Peptides identified by the mass mapping procedure and relative to: isolated ICOSL, isolated ICOSL+DTSSP (indicated
with CL); OPN/ICOSL complex +DTSSP (indicated with CL); OPN/ICOSL+DTSSP (indicated with CL) following reduction and
alkylation treatment (indicated with CAM).
Lysine
Residue
Peptides from ICOSL Peptides from (ICOSL+
DTSSP)
Peptides from the complex
(OPN/ICOSL+DTSSP)
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shows that ICOSL expression in HUVECs is required for their
migratory response to OPN in vitro.
The functional relevance of the OPN/ICOSL interaction in
tumor-cell migration was highlighted by data showing that
ICOSL expression in tumor cells is required for their migratory
response to OPN. The functional effect of OPN on triggering cell
migration needs the entire ICOSL molecule: it is lost when cells
express truncated forms of ICOSL, lacking either the extracellular
or the intracellular portion. However, attempts to identify this
signaling directly by Western blot, by comparing wide phos-
phorylating events triggered by OPN in cells expressing or not
expressing ICOSL, were inconclusive probably because of the
multiple signaling pathways triggered by OPN, that interact
contemporarily with its multiple receptors expressed on the same
cells, comprising several integrins and CD44, beside ICOSL.
In this light, it is worth noting that the cross-linking experi-
ments suggest that, upon its binding to ICOSL, the C-terminal
portion of OPN, involving the residues K170, K172, and K173,
located close to the ICOSL binding site, undergoes a conforma-
tional change, which might influence the accessibility to integrin
of the nearby RGD motif of OPN. The flexible and dynamic
structure of OPN enables it to adopt different functional struc-
tures, i.e. folding upon binding, while permitting it to enter into
multiple interactions with different binding partners16. It is,
therefore, possible that OPN acts as a scaffold, that can interact
contemporarily with several different cell-surface receptors, and
its interaction with ICOSL might modulate this activity. This
would be in line with the hypothesis that integrins co-operate
with other receptors (e.g.: RTK, Tie2, and growth hormones
receptors) on the cell surface28. However, the present findings
indicate ICOSL to be an essential component of the signaling
machinery recruited by soluble OPN, and it appears to be abso-
lutely required for soluble OPN-induced motility even in the
presence of integrins. This requirement might be due to the
Fig. 5 Conformational analysis of the OPN/ICOSL complex. a Model for ICOSL created with the SWISS-MODEL server using 4f9p.1.A (CD277/
Butyrophilin-3) as a template. Residues buried at the interface with ICOS are blue stained, K174 is red stained. b OPN is an intrinsically disordered protein
that simultaneously exhibits extended, random coil-like conformations and stable, cooperatively-folded conformations16. OPN model from Dianzani et al.,
201734. RGD in red, K170, K172, and K172 in blue, while K290, K292, and K296 are in green. Thrombin cleavage site (RS) is shown in pink.
Fig. 6 ICOSL binds both the N-term and the C-term thrombin-generated fragments of OPN. a Western blot showing the OPN recombinant proteins (FL:
full length, N and C-terminal fragments) probed with the anti-His-tag antibody (uncropped blot is shown Supplementary Fig. 6); b ELISA-based interaction
assay. The graph shows the interaction of titrated amounts of soluble ICOSL-Fc with a fixed amount of OPN-FL, OPN N- or C-fragments coated on the
plate. (black circle) shows OPN full length, (black square) OPN-N and (black triangle) OPN-C. Data are expressed as means ± standard error (n= 3
technical replicates).
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mechano-sensing nature of integrins, which require traction for
full activation, making soluble molecules poor activators29.
The pro-migratory effect of OPN binding to ICOSL is dom-
inantly antagonized by ICOS, since ICOS-Fc inhibits OPN-
induced migration, even though this effect is not specific for
OPN. However, ICOS-Fc can also display specific inhibitory
effects on other OPN activities. On the one hand, ICOS-Fc
inhibits ERK phosphorylation induced by OPN but not that
induced by ATP8, while on the other hand, ICOS-Fc inhibits
HUVEC tubulogenesis induced by OPN, but not that induced by
VEGF-α19.
An intriguing point is that, in 4T1ICOSL cells, expression of
ICOSL confers a dual response to OPN, which not only stimulates
cell migration but also inhibits anchorage-independent growth in
soft agar, whereas no effect is exerted on anchorage-dependent
growth in cell culture wells. The different effect of OPN on the
two types of growth might depend on the presence of strong
integrin signals in anchorage-dependent growth, which may
overcome negative effects mediated by OPN.
These results outline a scenario in which OPN/ICOSL inter-
action could play a dual role during tumor development by
decreasing primary local tumor growth, and, in parallel, by
mediating pro-invasive signals thus sustaining cancer cell dis-
semination. Although further experiments are needed to better
clarify the role of OPN/ICOSL interaction in metastatic dis-
semination in vivo, this model would challenge the literature
showing that primary 4T1 tumors disseminate cells to distant
sites in function of the size of primary tumors, with large tumors
producing more metastases than small ones30. Herein, we show
that ICOSL overexpression seems to be correlated with acquired
migration capabilities in response to OPN, also in the case of
smaller primary tumors. Noteworthy, ICOSL is highly expressed
in invasive breast carcinoma with poor prognosis31 and several
primary tumors, including breast cancer, acquire OPN expression
at the step of tissue invasion and metastatic dissemination.
Moreover, the present results suggest that ICOSL and OPN
expression may build up an autocrine loop, since forced expres-
sion of ICOSL in 4T1 cells correlated with increased production
of OPN in these cells.
It has recently been shown that the metastatic potential of
4T1 cells is greatly reduced in OPN−/− mice, whereas primary
tumor growth is unaffected32. This shows that stromal-derived
OPN is involved in metastatic dissemination of these cells, but
provides no information concerning the effect on ICOSL, which
is not expressed in wild-type 4T1 cells.
A recent report shows that ICOSL also binds to αvβ3 integrin,
through an RGD motif that is located in the membrane-distal IgV
domain of human ICOSL33, whereas in the mouse, it is located in
the membrane proximal to the IgC domain. This is intriguing,
since αvβ3 integrin is a known ligand also of the RGD motif
displayed by OPN, and it suggests that αvβ3 integrin may play a
role in the complex interaction between ICOSL and OPN, and
also in the conformational changes of OPN acting as a scaffold of
multiple receptors on the cell surface.
In conclusion, this study shows that ICOSL is a receptor for
OPN, interacting at a different domain of that used by ICOS.
ICOSL binding by ICOS or OPN exerts opposing effects on cell
migration, which is induced by OPN and dominantly inhibited by
ICOS. The ICOS effect appears to be mediated by direct signaling
through ICOSL, which has been demonstrated in several contexts,
and which is capable of inhibiting cell migration induced by
several chemotactic factors besides OPN. The OPN effect might
be mediated by direct signaling through ICOSL, or by the inte-
gration of multiple signals triggered by OPN, acting as a scaffold
on multiple cell receptors, including ICOSL, CD44, and several
integrins. In the light of the emerging role of the ICOS/ICOSL/
OPN trio in cancer progression, inflammation, adaptive immu-
nity, and bone metabolism, this trio might be targeted in various
ways in order to influence these processes in several human
diseases.
Methods
Cell lines and reagents. The tumor-cell lines were grown in culture dishes as a
monolayer in RPMI 1640 medium plus 10% fetal bovine serum (FBS) (Life
Fig. 7 ICOSL expression promotes tumor-cell migration while inhibiting
anchorage-independent cell growth. a Migration assay of 4T1 and 4TICOSL
cells in response to OPN or ICOS-Fc, assessed via a Boyden chamber assay.
4T1 and 4TICOSL cells were plated onto the apical side of Matrigel-coated
filters in 50 μl serum-free medium in the presence or not of ICOS-Fc
(2 μg ml−1). OPN or FBS loaded in the basolateral chamber as chemotactic
stimulus. The cells that migrated to the bottom of the filters were stained
with crystal violet and all counted (quadruplicates filters) using an inverted
microscope. The dotted line refers to untreated cells (NT). Data are
expressed as the number of migrated cells per high-power field, ***P <
0.001 refers to baseline, ###P < 0.001 refers to OPN-induced migration,
one-way ANOVA with the post-hoc Tukey multi-comparison test was used
(n= 4 technical replicate); b Anchorage-independent growth soft agar
assay of 4T1 and 4T1ICOSL transfected cells in response to OPN or PBS
(NT). Colonies were counted using Image J Software. The images from one
representative experiment are also shown. Please note that images are not
fully self-explanatory of each histogram. For the comparison of 4T1 vs
4T1ICOSL cells, the T test was used. For the comparison of 4T1ICOSL,
4T1ICOSL+OPN one-way ANOVA with the post-hoc Tukey multi-
comparison test was used (*P < 0.05, ** P < 0.01, *** P < 0.001). (n= 3–5
technical replicate). All data are expressed as means ± standard error.
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technologies, Carlsbad, California, USA) 100 Uml−1 penicillin, and 100 μg ml−1
streptomycin at 37 °C in 5% CO2-humidified atmosphere. The following tumor-cell
lines were used: JR8, M14, PCF2, A2058 (human melanoma) Rajj (human Burkitt’s
lymphoma) and 4T1 (mouse breast cancer) purchased from the American Type
Culture Collection (ATCC; Virginia, USA).
HUVECs were isolated from human umbilical veins by trypsin treatment (1%)
and cultured in M199 medium (Life technologies, Carlsbad, California, USA), with
the addition of 20% FBS, 100 U ml−1 penicillin, 100 μgml−1 streptomycin, 5 UI ml−1
heparin, 12 μgml−1 bovine brain extract, and 200mM glutamine. HUVECs were
grown to confluence in flasks and used at passages two through five. The use of
HUVEC was approved by the Ethics Committee of the “Presidio Ospedaliero
Martini” of Turin and conducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from all donors. Cells were routinely
screened for the mycoplasma contamination by PCR. All mycoplasma tests
performed during this study showed negative.
cDNAs coding for the human and murine OPN were cloned by PCR into a
pUCOE expression vector as described elsewhere12 and stably transfected into
Chinese hamster ovary cells (CHOs). Cell supernatants were collected, and the
recombinant proteins were purified on a nickel-nitrilotriacetic agarose resin
(Qiagen, Limburg, Netherlands) and characterized by Western blotting using either
an antibody directed against the His tag (Tetra-His Antibody, Qiagen, Valencia,
CA, USA) or an anti-OPN polyclonal antibody (Millipore, Billerica, MA, USA).
cDNA human GST-OPN was cloned by PCR into p4t1 prokaryotic expression
vector using the following primers: OPN-GST-for: 5′-
CCGGATCCATACCAGTTAAACAGGCTG-3′, OPN-GST-rev: 5′-
CCCCTCGAGAATAGATACACATTCAACC-3′.
The OPN-GST fusion protein was transformed in Escherichia coli BL21 (DE3).
Bacteria were precultured overnight in 2xTY medium and diluted in 1 liter of the
same medium. The optical density (OD) was constantly monitored until it reached
an OD of 1.5. Protein expression was induced by the addition of 0.5 mM isopropyl
1-thio-β-D-galactopyranoside and following 90 min incubation at 37 °C. The cells
were then pelleted and resuspended in 30 ml of PBS, pH 7.4 and lysed following
eight cycles of sonication. Pellet and supernatant were separated by centrifugation,
and the supernatant was applied to a pre-equilibrated Glutathione Sepharose
column (GE Healthcare) and incubated for 1 h at 4 °C. The resin was washed
thoroughly with PBS, pH 7.4 10 mM GSH, and protein was eluted with buffer PBS,
pH 7.4 60 mM GSH.
Animals. For this study, adult female mice from the following four standard inbred
strains were used: C57BL/6 J (The Jackson Laboratory, Bar Harbor, ME, USA);
B6.129S6(Cg)-Spp1tm1Blh/J, also known as OPN−/− (The Jackson Laboratory);
B6.129P2-Icos<tm1Mak>/J also know as ICOS−/− (The Jackson Laboratory),
BALB/cOlaHsd, or BALB/c mice (Envigo, Huntingdon, UK); and MRL/MpJ-Faslpr/J,
Fig. 8 OPN/ICOSL binding modulates tumor growth, angiogenesis, and metastatization in vivo. a Schematic illustration of experimental in vivo approach
and images of excised 4T1and 4TICOSL tumors, where white arrows indicate metastases. b Primary tumor growth of 4T1 cells in comparison with 4TICOSL
cells. 0.1 × 106 4T1 and 4T1ICOSL cells were subcutaneously injected into the mammary fat pad of Balb/c mice (n= 8–9 biological replicate per group).
Tumor growth was monitored using a caliper by measuring tumor size in 3 cross-directions. The Mann–Whitney test was used to compare differences in
tumor growth between the two groups per day, **P < 0.01, ***P < 0.001. c Numbers of 4T1 and 4T1ICOSL tumor lung metastases at the end point (day 29).
d OPN and ICOSL protein level and localization were evaluated by confocal analysis. Images were quantified using ImageJ software which permits to
calculate the ratio between red (OPN) and green (ICOSL) channels; values are expressed as percentage of red-green co-staining. Dot plot shows OPN and
ICOSL fluorescence intensity colocalization (3–4 biological replicate) and the Mann–Whitney test was used. e PLA on primary tumor specimens showing
OPN–ICOSL interaction. f As assessed by confocal analysis of Meca32 immunostaining, vessel density in 4T1ICOSL tumors was significantly increased (by
26%) compared with wild-type 4T1. The percentage of surface area occupied by vessels was quantified as Meca32 positive staining. Results have been
analyzed using unpaired Mann–Whitney U test. Scale bars: 50 μm (n= 3–4 biological replicate). Four images at a magnification of ×40 were analyzed for
each sample, considering three mice per treatment group. All data are expressed as means ± standard error.
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commonly known as MRL-lpr (The Jackson Laboratory). Mice of the first four
strains were used at 8–10 weeks of age, while those of the latter strain were 12 weeks
old. All animals were maintained under pathogen-free conditions in the animal
facility of Università del Piemonte Orientale; they were fed ad libitum on rodent
chow and water was freely available in the home cages, the ambient temperature was
maintained at 21 ± 1 °C. All experimental procedures were conducted during the
light phase of a 12:12-h light:dark cycle. Experimental procedures were conducted,
following European guidelines, in accordance with both the University Ethical
Committee and the National Institutes of Health Ministry and Care Committee
(protocol number DB064.42), both of which approved the protocol.
Cell migration assay. In the Boyden chamber (BD Biosciences, San Jose, CA,
USA) 8 × 103 cells were plated onto the apical side of 50 mgml−1 Matrigel-coated
filters (8.2-mm diameter and 0.5-mm pore size; Neuro Probe; BIOMAP snc, Milan,
Italy) in serum-free medium with or without 2 μg ml−1 of ICOS-Fc (Bio-Techne,
Minneapolis, Minnesota, USA). Medium containing 20% FCS or 10 μg ml−1 rOPN
(Bio-Techne, Minneapolis, Minnesota, USA) was placed in the basolateral chamber
as a chemoattractant for the tumor, while 10 ng ml−1 VEGF-α as a chemoattractant
for HUVECs. The chamber was incubated at 37 °C under 5% CO2. After 8 h, cells
on the apical side were wiped off with Q-tips. Cells on the bottom of the filter were
stained with crystal violet and all counted (quadruplicate filters) with an inverted
microscope (magnification ×100). Data are shown as percentages of treated cell
migration versus control migration measured for untreated cells.
ICOSL cloning. RNA from Raji cell line (ATCC, Manassas, Virginia, USA) was
extracted using TRI reagent (Merck, Darmstadt, Germany). 1 μg of RNA was
retrotranscribed to cDNA using the QauntiTect Reverse Transcription Kit (Qiagen,
Hilden, Germany). cDNA of ICOSL was amplified using PCR with specific oli-
gonucleotides (ICOSL-For: 5′-GATGCTAGCATGCGGCTGGGCAGTCCTG-3′
and ICOSL-Rev: 5′-CTTAAGCTTTCAAACGTGGCCAGTGAGCTC-3′). After
PCR, the amplicon was purified and cloned into pcDNA 3.1 vector (Life tech-
nologies, Carlsbad, California, USA). To generate ICOSL without intracytoplasmic
domain (ICOSL-TL), the following primers were used, annealing to the ICOSL-
pcDNA expression plasmid (ICOSL-TL-for: 5′-ATAGGATCCCGCCACCATG
CGGCTGGGCAGTCCTG-3′ and ICOSL-TL-rev: 5′-CCGGAATTCCGCCACCA
TGCGGCTGGGCAGTCCTG-3′). To generate ICOSL without extracellular
domain (ICOSL-intracytoplasmic (ICOSL-IC)), the following primers were used
(ICOSL-IC-for: 5′-CATCACCATTGGAGCATCCTGGCTGTCC-3′ and ICOSL-
IC-rev: 5′-GTGATGGTGATCAGCTCGAAGGCTGCTG-3′). cDNA derived from
RNA extracted from mouse splenocytes was obtained using the above protocol.
cDNA of mouse ICOSL (mICOSL) was generated using the following primers
(mICOSL-for: 5′-GATGCTAGCATGCAGCTAAAGTGTCCCTG-3′ and
mICOSL-rev: 5′-CTTAAGCTTTCAGGCGTGGTCTGTAAGTTG-3′) and cloned
into pcDNA 3.1 vector. All constructs were transformed into JM109 bacteria
(Promega, Madison, Wisconsin, USA) and the resulting colonies were sequenced
by Sanger sequencing (Life technologies, Carlsbad, California, USA).
Cell transfection. A2058, 4T1 and HeLa cells were plated in 10 cm dish plates (106
cells/plate) for 24 h in complete medium RPMI-1640 (Lonza, Basel, Switzerland)
(A2059) or DMEM (Lonza, Basel, Switzerland) (Hela and 4T1). Cells were then
transfected with 10 μg of plasmid DNA and 30 μl of lipofectamine® 3000 (Life
technologies, Carlsbad, California, USA) and expression of ICOSL was evaluated,
after 48 h either with real-time PCR, using a specific probe for ICOSL, by flow
cytometry using PE-conjugated antibodies to human ICOSL (Bio-Techne, Min-
neapolis, Minnesota, USA), or by immunofluorescence using primary antibodies to
mouse ICOSL (Life technologies, Carlsbad, California, USA) followed by Alexa
Flour 555 secondary antibodies (Anti-goat, Life technologies, Carlsbad,
California, USA).
ICOSL silencing. HUVECs were seeded (1.5 ×105 well−1) on 6 well plates for 24 h,
and then ICOSL was silenced using lipofectamine® RNAiMAX transfection reagent
(Life technologies, Carlsbad, California, USA) with two siRNA targeting two dif-
ferent exons of ICOSL (oligo1: ICOSLGHSS177318 (5′-CAGCAGCCUUCGAG-
CUGAUACUCAG-3′ and 5′-CUGAGUAUCAGCUCGAAGGCUGCUG-3′) and
oligo2: ICOSLGHSS118565 (5′-GGCCCAACGUGUACUGGAUCAAUAA-3′ and
5′-UUAUUGAUCCAGUACACGUUGGGCC-3′) (Life technologies, Carlsbad,
California, USA).
Real-time PCR was used to evaluate the expression of ICOSL after silencing.
After 24 h, HUVECs were starved and RNA was isolated using TRI reagent (Merck,
Darmstadt, Germany). 1 μg of RNA was retrotranscribed to cDNA using the
QauntiTect Reverse Transcription Kit (Qiagen, Hilden, Germany). ICOSL
expression was evaluated with a gene expression assay amount. Real-time PCR was
performed using CFX96 System (Bio-Rad Laboratories, Hercules, California, USA),
samples were run in duplicate in a 10 μl final volume containing 1 μl of diluted
cDNA, 5 μl of TaqMan Universal PCR Master Mix (Life technologies, Carlsbad,
California, USA), and 0.5 μl of Assay-on Demand mix. The results were analyzed
with a ΔΔ threshold cycle method.
ELISA-based interaction assay. OPN (60 nM) (Bio-Techne, Minneapolis, Min-
nesota, USA) in PBS was used to coat Nunc MaxiSorp™ flat-bottom plates (Life
technologies, Carlsbad, California, USA) overnight at 4 °C. After one wash with
PBS+ 0.25% Triton X-100 (Merck, Darmstadt, Germany), 3% of Bovine Serum
Albumin (BSA) (Merck, Darmstadt, Germany) in PBS+ 0.05% Tween-20 (Merck,
Darmstadt, Germany) was added for 1 h at 25 °C. After three washes, the plate was
incubated with titrated amounts (from 60 nM to 1.8 nM) of ICOSL-Fc (Bio-Techne
system, Minneapolis, Minnesota, USA) in PBS+ 0.05% Tween-20 for 1 h at 25 °C
with or without 60 nM of ICOS-Fc (competition assay). After washing, ICOSL-Fc
binding to OPN was evaluated using HRP conjugated anti-human-IgG1 antibodies
(1:4000) (Dako, Santa Clara, California, USA) in PBS+ 0.05% Tween-20 for 1 h at
25 °C, followed by washing and addition of the TMB substrate (Merck, Darmstadt,
Germany). The reaction was stopped after 2 min with H2SO4 2 N (Merck,
Darmstadt, Germany) and absorbance was assessed at 450 nm using a Victor-X1
plate reader (Perkinelmer, Waltham, Massachusetts, USA).
For the reciprocal ELISA, 60 nM of ICOSL-Fc in PBS was used to coat the
ELISA plates and titrated amounts of OPN (from 60 nM to 1.8 nM) were incubated
in the wells to assess binding. After washing, the bound OPN was revealed using
biotinylated polyclonal anti-OPN antibodies (Bio-Techne, Minneapolis,
Minnesota, USA) with an incubation of 2 h at 25 °C; after three washes
Streptavidin-HRP (Bio-Techne, Minneapolis, Minnesota, USA) was added for 20
min at 25 °C; the signal was developed following the above protocols.
In other experiments, 60 nM of OPN-GST, OPNb or home-made OPN-FL were
used to compare the interaction between commercial OPN and the others, and 60
nM of OPN-N terminal and OPN-C terminal respectively were used to map the
interaction site of ICOSL-OPN following the below protocol.
Pull-down assay. ICOSL-Fc and poly-his-OPN (10 μg each; Bio-Techne system,
Minneapolis, Minnesota, USA) were co-incubated in PBS (1 ml) at room tem-
perature (r.t.) on rotation for 1 h. Then ICOSL-Fc was precipitated using
Sepharose-protein G (GE Healthcare, Chicago, Illinois, USA). Sample buffer with
20% of β-mercaptoetanhol (Merck, Darmstadt, Germany) was used to dissociate
the proteins, which were then run in SDS/PAGE followed by Western blotting
using 1 μg ml−1 of anti-OPN polyclonal antibodies (Bio-Techne system, Minnea-
polis, Minnesota, USA).
Limited Proteolysis experiments. Limited Proteolysis experiments were carried
out on commercial recombinant His-tagged Osteopontin (OPN), produced by
R&D (Minneapolis, Minnesota, US) in a mouse myeloma cell line, containing the
physiological post-translational modifications but lacking 15 aa of exon 5, on
ICOSL-Fc provided by R&D (Minneapolis, Minnesota, US) and on OPN/ICOSL-
Fc. The three samples were treated with trypsin and chymotrypsin (SigmaAldrich)
in phosphate Dulbecco’s buffer (pH= 7.4), following set-up experiments to opti-
mize enzyme:substrate (E:S) ratios for each protein. For both proteases, the E:S
ratio was 1:5000 for both isolated OPN and OPN/ICOSL-Fc complex and 1:100 for
isolated ICOSL-Fc. In the complex analysis, OPN and ICOSL-Fc were pre-
incubated with 2:1 molar ratio for 1 h at r.t. before starting the proteolysis
experiment, in order to allow complex formation. Enzymatic digestions were run
for 30 min, after which 2% TFA was added to halt the reaction. The proteolysis
mixtures were resolved on a 15% acrylamide SDS-PAGE gel, and differential bands
were cut and subjected to in situ hydrolysis with trypsin, following the protocol
reported in Medugno et al., 200322. Tryptic peptide mixtures were analyzed both by
4800 MALDI TOF/TOF Analyzer (Sciex, Framingham, Massachusetts, USA) and
by nanoLC-MS/MS using a Proxeon-nanoEasy II-LTQ Orbitrap XL (Life tech-
nologies, Carlsbad, California, USA). In this latter, peptide fractionation was per-
formed on a C18 capillary reverse-phase column (200 mm, 75 µm, 5 µm) working
at 250 nl min−1 flow rate, using a step gradient of eluent B (0.2% formic acid, 95%
acetonitrile LC-MS Grade) from 10 to 60% over 69 min and 60 to 95% over 3 min.
Mass spectrometric analyses were performed using data-dependent acquisition
(DDA) mode over the 400 to 1800m z−1 range, followed by acquisition in MS/MS
mode of the five most abundant ions present in each MS scan. Peptides were
identified using MASCOT software (Matrix Science Boston, USA) searching in a
database containing only OPN and ICOSL-Fc sequences.
Cross-linking experiments. In-house purified GST-OPN (OPNa acccession
number NP_001035157.1) and His-tagged ICOSL (Bio-Techne, Minneapolis,
Minnesota, US) were pre-incubated at 2:1 molar ratio for 1 h at r.t., as described
above, and once the complex was formed the DTSSP cross-linker (3,3′-dithiobis
(sulfosuccinimidyl propionate, Life technologies, Carlsbad, California, USA) was
added in a molar excess of 1:50 and incubated for 30 min at 4 °C. The reaction
mixtures were loaded onto 8% non-reducing SDS-PAGE gel. Bands corresponding
to isolated proteins and to the complex were excised from the gel and subjected to
in situ hydrolysis with trypsin, skipping the reduction and alkylation steps, to
preserve DTSSP disulfide integrity. Peptide mixtures were analyzed by MALDI-MS
and by nanoLC-MS/MS, as described above. Peptide identification was carried out
both manually and using software such as MASCOT and Batch-Tag, MS-Bridge
and MS-Product tools within the Protein Prospector package. An aliquot of each
peptide mixture was reduced in 20 mM ditiothreitol for 2 h at 37 °C and then
alkylated with 55 mM of iodoacetamide for 30 min in the dark at r.t.; the mixtures
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thus obtained were analyzed by MALDI-MS and nanoLC-MS/MS, as
described above.
4T1 breast cancer mouse model. To evaluate tumor growth and tumor metas-
tatization, 1 × 105 4T1 and 4T1ICOSL cells were injected into the fat pad of 8–10-
week-old BALB/c female mice (Envigo, Huntingdon, UK). Tumor growth was
evaluated using a caliper, starting when the tumors became palpable, every two
days for 29 days from cell injection. At the end point, the mice were anesthetized to
allow intracardiac collection of the blood, then sacrified. Superficial pulmonary
metastases were contrasted by black India-ink intratracheal infusion and counted
on explanted lung lobes under a stereoscopic microscope. The numbers of lung
metastases were counted by two observers working blind.
Immunofluorescence on animal specimens. After death, all animals underwent
complete necropsy. Kidney, spleen, liver, lung, heart, and brain were weighed and
macroscopically analyzed. Immediately after dissection, only kidney and tumors
were embedded in OCT compound (Killik, Bioptica, Milan, Italy), and stored at
−80 °C until use. 10 µm sections were cut using a cryostat (Leica). For immuno-
fluoresce analysis sections were air-dried, fixed in zinc fixative (6.05 g Tris, 0.35 g
Ca (C2H3O2)2, 2.5 g Zn (C2H3O2)2, 2.5 g ZnCl, 3.8 ml HCl 37%) for 10 min at r.t.
and permeabilized with PBS+ 0.1 % Triton X-100 (Merck, Darmstadt, Germany)
for 5 min at r.t. Tissues were then blocked with 3% BSA and 3% donkey serum in
PBS (blocking solution) for 1 h at r.t. After quickly washing in PBS 1x, tissues were
incubated either for 1 h at r.t. or overnight at 4 °C with the following primary
antibodies: rabbit polyclonal anti-ICOSL (Antibodies online, Aachen, Germany),
goat polyclonal anti-OPN (Abcam, Cambridge, UK) or rat monoclonal anti-
panendothelial cell antigen (clone Meca32, BD Pharmingen), all diluted 1:100 in
blocking solution. After three washing in PBS 1x, tumors were incubated for 1 h at
r.t. with the following secondary antibodies: Alexa 555 donkey anti-goat and Alexa
488 donkey anti-rabbit or Alexa 488 donkey anti-rat (Life technologies, Carlsbad,
California, USA), diluted 1:400 in PBS.
Sections were then rinsed three times in PBS 1× and stained with 0.5 mg ml−1
of the fluorescent dye 4,6-diamidino-2-phenylindole-dihydrochloride (DAPI)
(Merck, Darmstadt, Germany) for 5 min, to color the cell nuclei. Slides were
mounted using Prolong anti-fade mounting medium (Slow Fade AntiFADE Kit,
Molecular Probes, Invitrogen). Images of the sections were acquired with a Leica
TCS SP2 AOBS confocal laser-scanning microscope (Leica Microsystems)
equipped with a ×20 or ×40 objective lens. Images were quantified using ImageJ
software which permits to calculate the ratio between red (OPN) and green
(ICOSL) channel; values are expressed as percentage of red-green co-staining. Four
images at a magnification of ×40 were analyzed for each sample, considering three
mice per treatment group.
Tumor vasculature quantification. Tumor vasculature was quantified by means
of ImageJ software as the area occupied by Meca32-positive structures, compared
with the total tissue area. Four images at a magnification of ×20 were analyzed for
each sample, considering three mice per treatment group.
Proximity ligation assays (PLA). PLA is a powerful tool that allows in situ
detection of protein interactions with high specificity and sensitivity. This tech-
nique uses one pair of primary antibodies, raised in different species, to target
proteins of interest whose interaction is to be studied. The kit includes a pair of
oligonucleotide-labeled secondary antibodies (PLA probes), ligation and DNA
polymerase. If the proteins of interest are closer than 40 nm, the secondary oligos
couple and the fluorochromes hybridize; after signal amplification, the result is
then viewable as discrete spots.
The concentrations for immunostaining of anti-OPN and ICOSL primary
antibodies were previously optimized as described above. Kidney tissues from
C57Bl/6 J mice and breast tumors from 4T1 were firstly processed as described
above for immunofluorescence and incubated with anti-OPN and anti-ICOSL
overnight at 4 °C. PLA analysis was then carried out using the Duolink® In Situ Far
Red Starter Kit Goat/Rabbit (# DUO92008) according to the manufacturer’s
protocol (Merck, Darmstadt, Germany). Additional reagents were used: Duolink®
In Situ PLA® Probe Anti-Goat MINUS (# DUO92006, Merck) and Duolink® In
Situ PLA® Probe Anti-Rabbit PLUS (# DUO92002, Merck), Duolink® In Situ Wash
Buffers, Fluorescence (# DUO82049, Merck) and Duolink® In Situ Mounting
Medium with DAPI (# DUO82040, Merck). Images were acquired with a Leica
TCS SP2 AOBS confocal laser-scanning microscope (Leica Microsystems).
Statistics and reproducibility. Details on statistical analyses and number of
biological replicates (n) can be found in the figure legends. Experiments were set up
with, at least, three replicates for each sample unless otherwise stated. P values
below 0.05 were considered statistically significant. The statistical analyses were
performed with GraphPad Instat software (GraphPad Software). All data sources
underlying the figure graphs, are included in Supplementary Data 1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are included
within the article or supplementary files and are available from the corresponding author
upon reasonable request. New plasmids reported in this study (huICOSL-FL, huICOSL-
TL, huICOSL-IC, Ms ICOSL, huGST-OPN) will be available via Addgene.
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